STOP PRESS: Phase 2 data  Patients receiving INV102 (nadolol)...

  1. 1,072 Posts.
    lightbulb Created with Sketch. 126
    STOP PRESS: Phase 2 data  Patients receiving INV102 (nadolol) were more likely to stop smoking completely or dramatically reduce the number of cigarettes smoked  INV102 (nadolol) significantly decreases key mucous metaplasia biomarker MUC5AC  Invion requests FDA End of Phase 2 meeting and submits abstract to 2016 American Thoracic Society (ATS) annual meeting

    Looks like the CR has been extended now to 7 Dec. 2015. Possibly a sign of low interest? or the company needs more time to really get the message out. Seems like comms are an afterthought.
    Last edited by twigman7: 25/11/15
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.9¢
Change
0.003(3.13%)
Mkt cap ! $8.456M
Open High Low Value Volume
9.6¢ 9.9¢ 9.6¢ $4.722K 48.38K

Buyers (Bids)

No. Vol. Price($)
2 73355 9.6¢
 

Sellers (Offers)

Price($) Vol. No.
9.9¢ 49950 1
View Market Depth
Last trade - 13.17pm 01/08/2025 (20 minute delay) ?
IVX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.